Sucampo Announces Extension of AMITIZA(R) (lubiprostone) License and Collaboration Agreement With Takeda
October 14, 2014 06:45 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Oct. 14, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it signed on October 9, 2014 an...
Clinical Data for AMITIZA(R) Lubiprostone to be Presented at the American College of Gastroenterology 2014 Annual Scientific Meeting
October 13, 2014 06:45 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Oct. 13, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that clinical data for AMITIZA®...
Sucampo and Takeda Launch Direct-to-Consumer Advertising Campaign for AMITIZA(R) (lubiprostone) for Chronic Idiopathic Constipation
September 29, 2014 06:45 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Sept. 29, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP) and its development and commercialization partner, Takeda Pharmaceuticals (Takeda), today...
Sucampo Announces New Exclusive Global Manufacturing and Supply Agreement for Lubiprostone
August 21, 2014 16:30 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Aug. 21, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that its subsidiary, Sucampo AG, has signed...
Sucampo Announces Publication of NICE Recommendation for AMITIZA(R) (Lubiprostone)
July 23, 2014 06:45 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Maryland and ABINGDON, Oxfordshire, July 23, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that the...
Sucampo Announces Clinical Data on Lubiprostone to be Presented at Two Upcoming Scientific Conferences
May 01, 2014 06:45 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., May 1, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. ("Sucampo") (Nasdaq:SCMP), a global biopharmaceutical company, today announced that clinical data for lubiprostone will be...
Sucampo and Takeda Announce Update on Liquid Formulation Program for AMITIZA(R) (lubiprostone)
March 14, 2014 17:29 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., March 14, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharma Americas, LLC, a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), and its development and...
Sucampo and Takeda Initiate Global Pivotal Phase 3 Program of Lubiprostone in Pediatric Functional Constipation
December 17, 2013 06:45 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md. and DEERFIELD, Ill., Dec. 17, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") and its development and commercialization partner Takeda Pharmaceuticals...
Sucampo and Takeda Initiate Pivotal Trial of Lubiprostone Liquid Formulation in Adults With Chronic Idiopathic Constipation
October 23, 2013 06:45 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md. and DEERFIELD, Ill., Oct. 23, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") and its development and commercialization partner Takeda Pharmaceuticals...
Sucampo Announces Presentation of Results on AMITIZA(R) (lubiprostone) in Opioid-Induced Constipation at Two Upcoming Scientific Conferences
October 11, 2013 06:45 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Oct. 11, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo") today announced the presentation of three posters evaluating AMITIZA® (lubiprostone) in...